Cell Surface Proteoglycans as Potential Targets for Immunotherapy in Women’s Cancer

Triple negative breast cancers constitute approximately 15-20% of all breast cancers and they are more aggressive compared to other phenotypes (e.g. Luminals A and B and Her2+). Additionally, triple negative breast cancers are harder to treat because of the absence of targets for hormonal therapies such as ER, PR, and Her2+. Presently, there are only limited neoadjuvant therapy regimens available that weaken or shrink triple negative breast cancer cells prior to surgical resection. Thus, one immediate requirement for the treatment of triplenegative breast cancer is to characterize and evaluate molecules that play important roles in promoting malignant phenotypes and to develop novel strategies that interfere with the functions of these proteins.